Press Releases Calliditas Therapeutics AB

Equities

CALTX

SE0010441584

Real-time Estimate Cboe Europe Other stock markets 06:55:50 2024-04-29 am EDT			5-day change	1st Jan Change
105.6 ^SEK	+1.78%		+4.69%	-17.39%

Apr. 25	European Equities Traded in the US as American Depositary Receipts Trend Modestly Higher in Thursday Trading	MT
Apr. 24	Calliditas Therapeutics Says OLE Study Shows Treatment Response Consistent With Late-Stage NefIgArd Study's Findings	MT

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Calliditas Therapeutics' 2023 Annual Report Published	Apr. 24	AQ
Calliditas Announces Positive NefIgArd Open Label Extension Results	Apr. 24	AQ
Calliditas Therapeutics Presents Additional Data Analyses from the Phase 3 NeflgArd trial of Nefecon in Primary IgA Nephropathy at the ISN World Congress of Nephrology 2024	Apr. 18	AQ
Calliditas Therapeutics to Attend Conferences in April	Apr. 09	AQ
Calliditas Therapeutics to Present Nefecon Data at the ISN World Congress of Nephrology April 13 - 16 in Buenos Aires	Apr. 08	AQ
Calliditas receives notice of allowance for United States patent application covering setanaxib in cancer treatment	Apr. 08	AQ
Calliditas Therapeutics : February 21, 2024 Year-end report 2023 (Presentation)	Mar. 14	PU
Calliditas announces an additional seven year orphan drug exclusivity Period for TARPEYO	Mar. 07	AQ
Calliditas announces an additional seven year orphan drug exclusivity period for TARPEYO®	Mar. 06	AQ
Calliditas Therapeutics to Attend Investor Conferences in March	Mar. 04	AQ
Calliditas Therapeutics to Attend Investor Conferences in March	Mar. 01	AQ
Calliditas Year-end report, January - December 2023	Feb. 21	AQ
Invitation to the presentation of Calliditas' Year-end report January - December 2023	Feb. 14	AQ
Calliditas provides patent update	Feb. 13	AQ
Calliditas Therapeutics appoints Maria Tornsen as President North America	Jan. 08	AQ
Calliditas Therapeutics provides business update ahead of JP Morgan conference	Jan. 08	AQ
Calliditas Therapeutics appoints Maria Törnsén as President North America	Jan. 07	AQ
Calliditas to present at JP Morgan Healthcare Conference	Jan. 07	AQ
Calliditas refinances existing term loan with Euro 92 million senior secured facility with Athyrium Capital	Dec. 27	AQ
Everest Medicines Partner Calliditas Therapeutics Announces Nefecon the Only FDA-approved Treatment for IgA Nephropathy to Significantly Slow Kidney Function Decline	Dec. 22	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Calliditas Therapeutics AB

Equities

CALTX

SE0010441584

Press Releases

Filters